Verrica Pharmaceuticals (1NE0) Stock Forecast & Price Target

Compare

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1NE0 Analyst Ratings

Moderate Buy

2 Buy

0 Hold

0 Sell

Based on 2 analysts giving stock ratings to

Verrica

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1NE0 Stock 12 Month Forecast

Average Price Target

€15.69

▲(247.12% Upside)

Based on 2 Wall Street analysts offering 12 month price targets for Verrica Pharmaceuticals in the last 3 months. The average price target is €15.69 with a high forecast of €16.96 and a low forecast of €14.42. The average price target represents a 247.12% change from the last price of €4.52.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","17":"€17","5.75":"€5.75","9.5":"€9.5","13.25":"€13.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16.9622048,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€16.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.69003944,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€15.69</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.41787408,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€14.42</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,5.75,9.5,13.25,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.3,7.1201696,7.9403391999999995,8.7605088,9.5806784,10.400848,11.2210176,12.0411872,12.8613568,13.6815264,14.501695999999999,15.321865599999999,16.1420352,{"y":16.9622048,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.3,7.0223107261538456,7.744621452307692,8.466932178461537,9.189242904615384,9.91155363076923,10.633864356923077,11.356175083076923,12.078485809230768,12.800796535384613,13.52310726153846,14.245417987692306,14.967728713846153,{"y":15.69003944,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.3,6.924451852307692,7.548903704615384,8.173355556923077,8.797807409230769,9.42225926153846,10.046711113846154,10.671162966153846,11.295614818461537,11.92006667076923,12.544518523076924,13.168970375384614,13.793422227692307,{"y":14.41787408,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.58,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.214,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.234,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.966,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.282,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.17,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.84,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.685,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 58, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 47, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.3,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€16.96

Average Price Target€15.69

Lowest Price Target€14.42

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Stacy Ku

TD Cowen

€16.91

Buy

274.11%

Upside

Initiated

01/07/26

Analysts Offer Insights on Healthcare Companies: Globus Medical (NYSE: GMED) and Verrica Pharmaceuticals (NASDAQ: VRCA)

Kemp Dolliver

Brookline Capital Markets

€14.37

Buy

218.00%

Upside

Upgraded

12/17/25

Verrica Pharmaceuticals upgraded to Buy from Hold at BrooklineVerrica Pharmaceuticals upgraded to Buy from Hold at Brookline

Serge Belanger

Needham

―

Hold

―

Reiterated

11/24/25

Verrica Pharmaceuticals: Hold Rating Amid Strategic Debt Retirement and Dilution Concerns

Dev Prasad

Lucid Capital

€16.06

Buy

255.41%

Upside

Initiated

11/05/25

Verrica Pharmaceuticals initiated with a Buy at Lucid CapitalVerrica Pharmaceuticals initiated with a Buy at Lucid Capital

Gregory Renza

Truist Financial

€16.91

Hold

274.11%

Upside

Reiterated

05/13/25

RBC Capital Reaffirms Their Hold Rating on Verrica Pharmaceuticals (VRCA)

Oren Livnat

H.C. Wainwright

―

Hold

―

Reiterated

04/07/25

Hold Rating on Verrica Pharmaceuticals Amid Liquidity Concerns and Uncertain Financial Strategy

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Stacy Ku

TD Cowen

€16.91

Buy

274.11%

Upside

Initiated

01/07/26

Analysts Offer Insights on Healthcare Companies: Globus Medical (NYSE: GMED) and Verrica Pharmaceuticals (NASDAQ: VRCA)

Kemp Dolliver

Brookline Capital Markets

€14.37

Buy

218.00%

Upside

Upgraded

12/17/25

Verrica Pharmaceuticals upgraded to Buy from Hold at BrooklineVerrica Pharmaceuticals upgraded to Buy from Hold at Brookline

Serge Belanger

Needham

―

Hold

―

Reiterated

11/24/25

Verrica Pharmaceuticals: Hold Rating Amid Strategic Debt Retirement and Dilution Concerns

Dev Prasad

Lucid Capital

€16.06

Buy

255.41%

Upside

Initiated

11/05/25

Verrica Pharmaceuticals initiated with a Buy at Lucid CapitalVerrica Pharmaceuticals initiated with a Buy at Lucid Capital

Gregory Renza

Truist Financial

€16.91

Hold

274.11%

Upside

Reiterated

05/13/25

RBC Capital Reaffirms Their Hold Rating on Verrica Pharmaceuticals (VRCA)

Oren Livnat

H.C. Wainwright

―

Hold

―

Reiterated

04/07/25

Hold Rating on Verrica Pharmaceuticals Amid Liquidity Concerns and Uncertain Financial Strategy

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Verrica Pharmaceuticals

3 Months

xxx

Success Rate

4/11 ratings generated profit

Average Return

-7.91%

initiated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 36.36% of your transactions generating a profit, with an average return of -7.91% per trade.

1 Year

Stacy KuTD Cowen

Success Rate

1/11 ratings generated profit

Average Return

-50.35%

initiated a buy rating 2 months ago

Copying Stacy Ku's trades and holding each position for 1 Year would result in 9.09% of your transactions generating a profit, with an average return of -50.35% per trade.

2 Years

xxx

Success Rate

1/11 ratings generated profit

Average Return

-48.65%

initiated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 9.09% of your transactions generating a profit, with an average return of -48.65% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1NE0 Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1NE0 has received 5 Buy Ratings, 30 Hold Ratings, and 0 Sell Ratings. 1NE0 average Analyst price target in the past 3 months is 15.69.

Each month's total comprises the sum of three months' worth of ratings.

1NE0 Financial Forecast

1NE0 Earnings Forecast

Currently, no earnings data available.

1NE0 Sales Forecast

Currently, no sales data available.

1NE0 Stock Forecast FAQ

What is DE:1NE0’s average 12-month price target, according to analysts?

Based on analyst ratings, Verrica Pharmaceuticals’s 12-month average price target is 15.69.

What is DE:1NE0’s upside potential, based on the analysts’ average price target?

Verrica Pharmaceuticals has 247.12% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Verrica Pharmaceuticals a Buy, Sell or Hold?

Verrica Pharmaceuticals has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.

What is Verrica Pharmaceuticals’s share price target?

The average share price target for Verrica Pharmaceuticals is 15.69. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €16.96 ,and the lowest forecast is €14.42. The average share price target represents 247.12% Increase from the current price of €4.52.

What do analysts say about Verrica Pharmaceuticals?

Verrica Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.

How can I buy shares of Verrica Pharmaceuticals?

To buy shares of DE:1NE0, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Verrica Pharmaceuticals (1NE0) Stock Forecast & Price Target

1NE0 Analyst Ratings

1NE0 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Verrica Pharmaceuticals

1NE0 Analyst Recommendation Trends

1NE0 Financial Forecast

1NE0 Earnings Forecast

1NE0 Sales Forecast

1NE0 Stock Forecast FAQ

Detailed List of Analyst Forecasts